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The Challenge
The international humanitarian medi-
cal aid organization Me ´decins Sans Fron-
tie `res/Doctors Without Borders (MSF)
supports a wide network of medical la-
boratories in resource-constrained coun-
tries. Although MSF has always prioritized
quality control (QC) for laboratory testing,
prior to 2005 we were constrained by two
significant limitations. First the QC work-
load was unsustainable in many programs,
as MSF used the traditional protocol of
reexamining 10% of negative slides and all
positive slides. This is no longer considered
practical [1–3]. Second MSF had no
system for central data analysis as QC
was performed independently at the indi-
vidual laboratory level without standard-
ized protocols.
In May 2005, MSF Operational Cen-
tre Amsterdam (MSF-OCA) developed
and implemented a standardized, cen-
trally reporting QC program to monitor
the quality of microscopy for malaria,
pulmonary tuberculosis (TB), and leish-
maniasis. The malaria component of this
protocol has been adapted by the World
Health Organization (WHO) as the
recommended international standard
for malaria microscopy QC [4]. Here
we present a description of the QC
protocol and an analysis over a 3-year
period, the latter reflecting how the QC
protocol has contributed to improved
performance.
The Protocol
The QC protocol was designed to (1)
have a small sample size to be feasible
across all settings; (2) enable reliable
analysis; (3) monitor both false-positive
(FP) and false-negative (FN) results; and
(4) be applicable to all microscopy
testing.
Monthly QC Sample
Sample size. The MSF-OCA
protocol is based on a sample size of
ten slides/month/site (for each test), as
field experience has demonstrated that
this QC workload is sustainable in most
settings, and on the premise that it is
better to perform less QC well than
more QC poorly. A small sample size is
also important to avoid overloading
the limited capacity of the reference
laboratory in many resource-constrained
settings. Programs are encouraged to
include more QC slides if this can
be achieved without compromising the
quality of the reexamination.
Sample selection and reexamin-
ation. In summary, each month for
each test: (1) Five weak positive slides are
selected randomly from all weak positive
slides; or if ,5 weak positive slides, then
all weak positive slides are selected. (2) Five
negative slides are selected randomly from
all negative slides; or if ,5 negative slides,
then all negative slides are selected. (3) If
there are ,5 weak positive (or negative)
slides, then the number of negative (or
weak positive) slides is increased to give
a total minimum sample size of ten. (4)
Strong positive slides are excluded
from selection in the QC sample. (5)
Laboratories unable to perform QC on a
minimum of ten slides are assessed on an
individual basis.
Blinded QC slides are reexamined
within 4 weeks in the field by either a
reference laboratory or an independent
skilled laboratory technician.
Weak positive slides are defined as #9
trophozoites/acid-fast bacilli (AFB)/10
high power fields. These definitions were
consistent across laboratory sites. Postim-
plementation experience now suggests that
the criteria for a weak positive should
be reduced to #9 trophozoites/AFB/100
high power fields.
Protocol Reliability
While small sample QC has the impor-
tant advantage of practicality, maintain-
ing reliable analysis is also essential. To
compensate for the small number of QC
slides reexamined each month, our QC
protocol uses analysis of cumulative data
over 4-month periods (i.e., 4 months of
data), referred to here as ‘‘cohort analy-
sis’’. These 4-month cohorts are used to
increase the sample size analyzed, and as a
compromise between the greater statistical
stringency of analyzing a larger number of
results over a longer duration (e.g., 12
months) versus the greater immediacy
of detecting real-time laboratory perfor-
mance by analyzing QC over a shorter
period.
False-Positive and False-Negative
Analysis
To enable FP analysis on small samples,
our protocol uses biased sampling to
increase the number of positive slides
available for reexamination, and the
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discriminatory power.
Biased sampling. QC protocols that
use a small sample size with random
sampling of all slides, such as lot quality
assurance sampling (LQAS) [2], have the
potential disadvantage of being unable
to adequately monitor false positivity
because of insufficient positive slides at
low prevalence rates if QC results are
analyzed over short periods of time. To
address this, the MSF-OCA protocol uses
a biased QC sample of an equal number
(whenever possible) of weak positive and
negative slides to enable both FP and FN
analysis.
Targeting weak positives. The
protocol selects only weak positive
slides because errors of false positivity
are most likely to occur during routine
microscopy through microscopists report-
ing negative findings as weakly positive
(to be ‘‘on the safe side’’) [5], or through
the misidentification of artifacts as
parasites [1]. Using weak positive slides
also has greater discriminatory power
than reexamining strongly positive slides
[1,6,7].
However, because FP results are more
likely to occur among weak positive slides,
reexamining only weak positive slides
(rather than all positive slides) may over-
estimate the FP frequency in routine
microscopy. We correct for this by using
the formula:
Program FP rate~
QC FP rate|Total number of weak positive slides routinely examined
Total number of all positive slides routinely examined
A limitation of this correction is that it
assumes a negligible FP frequency for
strong positive slides.
Common Protocol for All
Microscopy
A primary objective for MSF-OCA was
to develop a protocol that could be used
for all microscopy testing. Although LQAS
is recommended by WHO and others for
AFB direct-smear TB analysis [3], we
found this methodology unsuitable for
malaria microscopy because determining
the LQAS sample size is problematic
when there is seasonal variation in the
positivity rate. Our protocol therefore uses
a fixed rather than variable number of QC
slides.
Laboratory Performance Analysis
All QC results were reported to the
central office in Amsterdam, which en-
abled comparative monitoring of results
across all programs and the identification
of poorly performing laboratories. Sum-
marized analysis was reported back to the
field to enable individual laboratories to
compare their performance to other lab-
oratories in similar settings.
We use percentage agreement because
it is simple, direct, and understandable at
all levels [1]. Laboratory performance was
considered satisfactory if the percentage
agreement between the laboratory results
and the reexamined results was equal to or
exceeded the internal standards set by
MSF-OCA (simple cut-off analysis).
Findings
In contrast to stable programs, such as
government health laboratory networks,
MSF operates as an emergency humani-
tarian organization, and laboratory pro-
grams open and close according to
changing priorities. Therefore the QC
analysis presented here reflects the overall
performance of MSF-OCA programs over
2005–2008 with a changing composition
of laboratories.
Because only a limited number of
laboratories performed leishmaniasis test-
ing, these findings are not presented here.
To improve statistical reliability, we
only analyzed percent agreement on
cohort data that included at least three
monthly reports in the 4-month period,
and FP and FN on cohort data that
included at least ten positive or ten
negative slides, respectively (Table 1).
Fifty-seven laboratories met these criteria
for malaria microscopy QC, and 54 for
TB.
During the reported period, the internal
MSF-OCA standards were set at $95%
agreement for all slides (percent agree-
ment) and #5% FP and FN slides.
Tests of difference between two propor-
tions were performed using the Pearson’s
Chi-squared test. Analysis was performed
using Epi Info 6 (US Centers for Disease
Control) and STATA version 8.2 (Stata-
Corp).
Malaria microscopy. Marked pro-
gressive improvement in the overall
malaria microscopy QC performance
was seen over the period (Figures 1 and
2; Table 2). At the commencement of the
QC program for the period May–
December 2005 (two cohorts), 32.3%
(10/31), 17.4% (4/23), and 58.1% (18/
31) of laboratories complied with the
percent agreement, FP, and FN targets,
respectively. By 2008, for the period
January–August (two cohorts), there were
significant improvements (p,0.001) in the
proportion of laboratories meeting each
QC target, with the results of 95.7% (45/
47), 86.7% (13/15), and 91.3% (42/46),
respectively.
AFB microscopy. Progressive im-
provement in the overall AFB micro-
scopy QC performance was seen over
Table 1. Laboratory QC data collection and analysis.
Data Collection and Analysis Malaria AFB
Total data collected Laboratories 72 62
Cohorts 329 325
Monthly reports 1,093 1,074
Percent-agreement analysis (excluding cohort data that included ,3 monthly reports) Laboratories 57 54
Cohorts 239 244
Monthly reports 908 929
False-positive analysis (excluding cohort data that included ,3 monthly reports and ,10 positive slides) Cohorts 151 177
Monthly reports 581 675
False-negative analysis (excluding cohort data that included ,3 monthly reports and ,10 negative slides) Cohorts 237 244
Monthly reports 901 929
doi:10.1371/journal.pmed.1000206.t001
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the commencement of the QC program
for the period May–December 2005 (two
cohorts), 59.1% (13/22) and 43.8% (7/16)
of laboratories complied with the percent
agreement and FP targets, respectively. By
2008, for the period January–August (two
cohorts), 82.1% (46/56; p=0.033) and
77.1% (27/35; p=0.019) of laboratories,
respectively, met these targets. In contrast,
the FN frequency remained relatively
constant throughout the period (Figure 3),
with no significant difference between the
May–August 2005 and May–August 2008
cohorts (90% and 96%, respectively,
p=0.527).
Lessons Learned
We found the design of our QC
protocol to be practical in field settings
and easily understood and implemented by
laboratory staff with limited training. We
attribute this to a combination of a small
QC sample size, a fixed number of slides
independent of the workload, and use of
simple percentage agreement for statistical
analysis. The small sample size consider-
ably decreased the QC workload while
maintaining statistical reliability by using
targeted sampling of only weakly positive
slides and 4-month cohort analysis.
Our findings show a significant im-
provement in the accuracy of malaria and
AFB microscopy comparing the periods
May–December 2005 and January–Au-
gust 2008. We attribute this improvement
to the strengthening of our protocols, field
support, and training over this period.
However our QC protocol also played a
central role by providing key information
on a timely basis allowing us to prioritize
those laboratory support activities. Also,
and we believe critically, the reporting of
compiled data back to the field provided
the laboratories with clear performance
indicators and enabled field laboratories
to directly compare their performance
against other laboratories working in
similar circumstances. In our experience,
this generated an environment of positive
‘‘competition’’ among laboratories that we
believe has also contributed significantly to
the improvement in laboratory quality
performance.
For malaria microscopy, the number of
FP and FN results decreased markedly.
We attribute this to active follow-up of
poorly performing laboratories identified
by the QC protocol. In contrast, the
frequency of FN results for AFB micros-
copy did not change significantly, and the
improvement in percentage agreement
reflects the decrease in the frequency of
FP results. Laboratories for AFB also
entered the analysis period at a higher
Figure 1. Percentage of laboratories and test centers achieving $95% agreement for malaria and AFB microscopy.
doi:10.1371/journal.pmed.1000206.g001
Figure 2. Percentage of laboratories and test centers achieving #5% false-positive and false-negative results for malaria
microscopy.
doi:10.1371/journal.pmed.1000206.g002
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malaria microscopy (59.1% of AFB co-
horts achieving $95% percentage agree-
ment for May–December 2005 compared
with 32.3% for malaria). This may be
because AFB microscopy is relatively
easier to perform than malaria microscopy
as accurate malaria microscopy requires
greater microscopy resolution and has a
technically more demanding staining
procedure.
However we also speculate that the
random selection of negative AFB smears,
which is the standard methodology for
AFB QC protocols and is used in our
protocol, may be problematic. Saliva
smears are in general more likely to be
negative or have an AFB density below the
threshold of microscopy detection than
sputum smears [8,9]. Therefore there is
less opportunity for QC to detect FN
results by reexamining saliva slides as they
have a higher prior probability of being
truly microscopically negative than a
sputum smear. With random selection,
laboratories with a high proportion of
saliva samples in routine practice will also
have a high proportion of saliva slides in
their QC sample, and therefore the QC
FN frequency for such laboratories may be
lower than their true FN frequency.
For the future, we are currently incor-
porating clerical error monitoring into
our laboratory QC protocol, as this can
also be a major source of error. With the
increasing emphasis on disease eradica-
tion, we are also developing QC protocols
to accommodate low positivity. Finally,
we have implemented a pilot study to
exclude saliva smears from the AFB QC
sample.
Conclusion
From this recent field experience, our
laboratory QC protocol was found to be
well accepted and understood by all levels
of field staff, practical in a wide variety of
contexts, able to improve performance,
and able to provide valuable program
management information. As with all QC,
implementation and sustainability requires
commitment from field staff and project
managers. Ongoing supervision and sup-
port are critical for central monitoring,
ensuring compliance, and regular feed-
back reporting. The implementation of
this centralized-reporting, standardized
QC program has provided the catalyst
for MSF-OCA to develop a laboratory
‘‘culture of quality’’ over the past 3 years,
which in turn has strengthened the
commitment and interest of laboratory
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